CN1111245A - 雪花胺衍生物、其制备方法及其作为药物的用途 - Google Patents
雪花胺衍生物、其制备方法及其作为药物的用途 Download PDFInfo
- Publication number
- CN1111245A CN1111245A CN94117060A CN94117060A CN1111245A CN 1111245 A CN1111245 A CN 1111245A CN 94117060 A CN94117060 A CN 94117060A CN 94117060 A CN94117060 A CN 94117060A CN 1111245 A CN1111245 A CN 1111245A
- Authority
- CN
- China
- Prior art keywords
- oxygen base
- carbonyl
- carbonyl oxygen
- hydrogen
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/06—Peri-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Psychiatry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
乙酰胆碱酯酶抑制测定 | |
化合物 | IC50uMCHE I |
[(6-O-脱甲基)-6-O-(1,2,3,4,-四氢异喹啉-2-基)羰基]雪花胺 | 0.0009 |
9-氨基四氢吖啶 | 0.32 |
化合物 | SDDA剂量(mg/kg,标准状况) | 莨菪胺诱发记忆缺乏反转的动物百分数 |
[(6-O-脱甲基)-6-O-(1,2,3,4-四氢异喹啉-2-基)羰基]雪花胺盐酸盐 | 0.003 | 27 |
9-氨基四氢吖啶 | 0.31 | 33 |
Claims (9)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US137440 | 1993-10-15 | ||
US137,440 | 1993-10-15 | ||
US08/137,440 US6323195B1 (en) | 1993-10-15 | 1993-10-15 | Galanthamine derivatives as acetylcholinesterase inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1111245A true CN1111245A (zh) | 1995-11-08 |
CN1039911C CN1039911C (zh) | 1998-09-23 |
Family
ID=22477446
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN94117060A Expired - Lifetime CN1039911C (zh) | 1993-10-15 | 1994-10-14 | 雪花胺衍生物、其制备方法及其作为药物的用途 |
Country Status (23)
Country | Link |
---|---|
US (2) | US6323195B1 (zh) |
EP (2) | EP0653427B1 (zh) |
JP (1) | JP2664344B2 (zh) |
KR (1) | KR0169114B1 (zh) |
CN (1) | CN1039911C (zh) |
AT (1) | ATE212348T1 (zh) |
AU (1) | AU696249B2 (zh) |
CA (1) | CA2118174C (zh) |
CZ (1) | CZ287071B6 (zh) |
DE (1) | DE69429708T2 (zh) |
DK (1) | DK0653427T3 (zh) |
EG (1) | EG20472A (zh) |
ES (1) | ES2171428T3 (zh) |
FI (1) | FI108723B (zh) |
IL (1) | IL111274A (zh) |
NO (1) | NO310415B1 (zh) |
NZ (1) | NZ264683A (zh) |
PL (1) | PL177730B1 (zh) |
PT (1) | PT653427E (zh) |
RO (1) | RO114133B1 (zh) |
RU (1) | RU2114850C1 (zh) |
TW (1) | TW363969B (zh) |
ZA (1) | ZA948062B (zh) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9514821D0 (en) * | 1995-07-19 | 1995-09-20 | Sod Conseils Rech Applic | Galanthamine derivatives |
AT403803B (de) * | 1996-04-19 | 1998-05-25 | Sanochemia Ltd | Neue benzazepinderivate, diese enthaltende arzneimittel und verwendung derselben zum herstellen von arzneimitteln |
JP5558648B2 (ja) | 1998-11-23 | 2014-07-23 | デイビス、ボニー | アセチルコリンエステラーゼ阻害剤のための投与製剤 |
PT1140105E (pt) | 1998-12-24 | 2004-03-31 | Janssen Pharmaceutica Nv | Composicao de galantamina de libertacao controlada |
US8603546B2 (en) * | 1999-01-11 | 2013-12-10 | Herbaceuticals Inc. | Herbal supplement for increased muscle strength and endurance for athletes |
ATE355066T1 (de) * | 1999-01-11 | 2006-03-15 | Atanas Russinov Djananov | Nahrungszusatz aus kräutern zur steigerung der muskulären kraft und ausdauer von athleten |
WO2000059544A1 (fr) * | 1999-03-31 | 2000-10-12 | Eisai Co., Ltd. | Compositions stabilisees contenant des medicaments nootropes |
KR100502391B1 (ko) * | 1999-10-26 | 2005-07-19 | 얀센 파마슈티카 엔.브이. | 갈란타민 및 감미제를 함유하는 경구 용액 |
CA2393301A1 (en) * | 1999-12-10 | 2001-06-21 | Bonnie Davis | Analogs of galanthamine and lycoramine as modulators of nicotinic receptors |
EP1181294B1 (de) | 2000-03-31 | 2004-03-31 | Sanochemia Pharmazeutika Aktiengesellschaft | Neue derivate und analoga von galanthamin |
US20030162770A1 (en) * | 2002-02-22 | 2003-08-28 | Davis Bonnie M. | Use of modulators of nicotinic receptors for treatment of cognitive dysfunction |
US20050143350A1 (en) * | 2003-11-19 | 2005-06-30 | Seed John C. | Combination drug therapy to treat obesity |
WO2005065661A2 (en) * | 2003-12-31 | 2005-07-21 | Actavis Group Hf | Immediate, controlled and sustained release formulations of galanthamine |
WO2005065662A1 (en) * | 2003-12-31 | 2005-07-21 | Actavis Group Hf | Solid dosage formulations of galantamine |
WO2006004201A1 (ja) * | 2004-07-01 | 2006-01-12 | Eisai R & D Management Co., Ltd. | 神経再生促進剤 |
EP2316437B1 (en) * | 2005-05-13 | 2014-07-30 | Alza Corporation | Multilayer drug delivery system with barrier against reservoir material flow |
US20080188510A1 (en) * | 2005-05-23 | 2008-08-07 | Eisai R & D Management Co., Ltd. | Novel methods using zonisamide |
JP2009508903A (ja) * | 2005-09-22 | 2009-03-05 | ガラントス ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング | 認知障害を伴う疾患の治療に用いるための脳血液関門透過性が改善されたコリン作用増強剤 |
US20090253654A1 (en) | 2005-09-22 | 2009-10-08 | Galantos Pharma Gmbh | Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment |
EP1777222A1 (en) | 2005-09-22 | 2007-04-25 | Galantos Pharma GmbH | Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment |
WO2007035941A2 (en) * | 2005-09-23 | 2007-03-29 | Alza Corporation | Transdermal galantamine delivery system |
ES2463715T3 (es) | 2008-04-14 | 2014-05-29 | Neurodyn Life Sciences Inc. | Derivados de galantamina como profármacos para el tratamiento de enfermedades del cerebro humano |
MX2012000939A (es) * | 2009-07-23 | 2012-06-08 | Shire Llc | Profarmacos de peptidos y aminoacidos de galantamina y usos de los mismos. |
WO2013160728A1 (en) | 2012-04-26 | 2013-10-31 | Alma Mater Studiorum - Universita' Di Bologna | Dual targeting compounds for the treatment of alzheimer's disease |
EP3628315A1 (en) | 2018-09-28 | 2020-04-01 | Université de Caen Normandie | Combination of acetylcholinesterase inhibitor and 5-ht4 receptor agonist as neuroprotective agent in the treatment of neurodegenerative diseases |
CN113292420A (zh) * | 2021-05-27 | 2021-08-24 | 神隆医药(常熟)有限公司 | 加兰他敏中间体原料2-溴-5-羟基-4-甲氧基苯甲酸回收方法 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL122665B1 (en) | 1978-11-21 | 1982-08-31 | Edinen Zentar Chim | Process for preparing novel dienones of narvedine type and their derivatives |
US4663318A (en) | 1986-01-15 | 1987-05-05 | Bonnie Davis | Method of treating Alzheimer's disease |
US6150354A (en) * | 1987-01-15 | 2000-11-21 | Bonnie Davis | Compounds for the treatment of Alzheimer's disease |
AU632458B2 (en) * | 1987-05-04 | 1993-01-07 | Bonnie Davis | Compounds for the treatment of alzheimer's disease |
NL8800350A (nl) | 1988-02-12 | 1989-09-01 | Stichting Biomedical Research | Synthetische galanthamine-derivaten, werkwijze voor het bereiden daarvan, en farmaceutische samenstellingen. |
DK0584185T3 (da) | 1991-05-14 | 2000-02-07 | Ernir Snorrason | Behandling af træthedssyndrom med cholinesteraseinhibitorer |
US5231093A (en) * | 1991-10-01 | 1993-07-27 | Hoechst-Roussel Pharmaceuticals Incorporated | Carbamate derivatives of 4-amino-3-isoxazolidinones, 3-amino-1-hydroxypyrrolidin-2-ones and 1-amino-1-cyclopropanecarboxylic acid analogs |
US5153193A (en) | 1991-10-01 | 1992-10-06 | Hoechst-Roussel Pharmaceuticals Incorporated | Carbamate derivatives of 4-amino-3-isoxazolidinones, 3-amino-1-hydroxypyrrolidin-2-ones and 1-amino-1-cyclopropanecarboxylic acid analogs |
-
1993
- 1993-10-15 US US08/137,440 patent/US6323195B1/en not_active Expired - Lifetime
-
1994
- 1994-10-10 DE DE69429708T patent/DE69429708T2/de not_active Expired - Lifetime
- 1994-10-10 DK DK94115959T patent/DK0653427T3/da active
- 1994-10-10 EP EP94115959A patent/EP0653427B1/en not_active Expired - Lifetime
- 1994-10-10 AT AT94115959T patent/ATE212348T1/de active
- 1994-10-10 EP EP00107570A patent/EP1020470A3/en not_active Withdrawn
- 1994-10-10 PT PT94115959T patent/PT653427E/pt unknown
- 1994-10-10 ES ES94115959T patent/ES2171428T3/es not_active Expired - Lifetime
- 1994-10-13 NZ NZ264683A patent/NZ264683A/en not_active IP Right Cessation
- 1994-10-13 EG EG64194A patent/EG20472A/xx active
- 1994-10-13 IL IL11127494A patent/IL111274A/xx not_active IP Right Cessation
- 1994-10-13 RU RU94036448A patent/RU2114850C1/ru active
- 1994-10-13 FI FI944821A patent/FI108723B/fi not_active IP Right Cessation
- 1994-10-14 RO RO94-01669A patent/RO114133B1/ro unknown
- 1994-10-14 CA CA002118174A patent/CA2118174C/en not_active Expired - Lifetime
- 1994-10-14 ZA ZA948062A patent/ZA948062B/xx unknown
- 1994-10-14 NO NO19943893A patent/NO310415B1/no not_active IP Right Cessation
- 1994-10-14 PL PL94305456A patent/PL177730B1/pl unknown
- 1994-10-14 CN CN94117060A patent/CN1039911C/zh not_active Expired - Lifetime
- 1994-10-14 AU AU75814/94A patent/AU696249B2/en not_active Expired
- 1994-10-14 CZ CZ19942546A patent/CZ287071B6/cs not_active IP Right Cessation
- 1994-10-14 TW TW083109526A patent/TW363969B/zh not_active IP Right Cessation
- 1994-10-14 KR KR1019940026303A patent/KR0169114B1/ko active IP Right Grant
- 1994-10-17 JP JP6250778A patent/JP2664344B2/ja not_active Expired - Fee Related
-
1995
- 1995-05-22 US US08/445,921 patent/US5777108A/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1111245A (zh) | 雪花胺衍生物、其制备方法及其作为药物的用途 | |
CN1039910C (zh) | 雪花胺衍生物、其制备方法及其作为药物的用途 | |
CN1037439C (zh) | 制备具有神经保护作用的吲哚酮及有关衍生物的方法 | |
CN1098255C (zh) | 新的具有速激肽受体拮抗活性的取代的哌嗪衍生物 | |
CN1028104C (zh) | 制备喹诺酮衍生物的方法 | |
CN1040985C (zh) | 苯并氮杂䓬类化合物的制备方法 | |
CN1028992C (zh) | 1,4,-苯并硫杂吖庚因衍生物的制备方法 | |
CN1430599A (zh) | 苯基甘氨酸衍生物 | |
CN1044816A (zh) | 关于有机化合物的改进 | |
CN1942437A (zh) | 作为环氧化酶-1-环氧化酶-2抑制剂的取代氮杂环丁烷化合物及其制备方法和作为药物的用途 | |
CN1759093A (zh) | 用于制备1,2-二氨基化合物的不使用叠氮化物的方法 | |
CN1108658A (zh) | 雪花胺衍生物及其制备方法和其作为药剂的用途 | |
CN1029968C (zh) | N-杂芳基-嘌呤-6-胺的制备方法 | |
CN1040440C (zh) | 去氢环黄皮酰胺衍生物的制备方法 | |
CN1215725A (zh) | 三萜衍生物及含有它们的内皮素-受体拮抗剂 | |
CN1048014C (zh) | 取代的吡咯类化合物及其制法、药物组合物和用途 | |
CN1043042C (zh) | 7-[2-(2-氨基噻唑-4-基)-2-(Z)-羟亚胺基-乙酰胺基]-3-(甲氧甲基)-3-头孢烯-4-羧酸-α-(2,2-二甲基丙酰氧)乙酯拆分的方法 | |
CN1751022A (zh) | 制备r,r(或s,s)构型的格隆铵-立体异构体的方法 | |
CN1126739C (zh) | 新的取代的四氢吡啶化合物、其制备方法及其药物组合物 | |
CN1092074A (zh) | 二氮杂䓬衍生物 | |
CN1019495B (zh) | 嘧啶衍生物的制备方法 | |
CN1054123C (zh) | 氨基甲酸衍生物的制备方法 | |
CN1042354A (zh) | (RS)-2-(2,3-二氢-5-羟基-4,6,7-三甲苯氧茚基)乙酸和2-2,3-二氢-5-乙酰氧基-4,6,7-三甲基氧茚基)乙酸及其酯,用作粘液调节剂和抗hyschaemic药物及其制备方法 | |
CN1025786C (zh) | 氨基甲酰基衍生物的制备方法 | |
CN87104641A (zh) | 4-(芳酰氨基)哌啶丁酰氨衍生物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee |
Owner name: ARWENDIE PHARMACY CORP. Free format text: FORMER NAME OR ADDRESS: HOECHST MARION ROUSSEL, INC. |
|
CP03 | Change of name, title or address |
Address after: new jersey Patentee after: Aventis Pharmaceuticals Inc. Address before: American Missouri Patentee before: Hoechst Marienrus Co. |
|
ASS | Succession or assignment of patent right |
Owner name: AVENTIS HOLDING CO.,LTD. Free format text: FORMER OWNER: ARWENDIE PHARMACY CORP. Effective date: 20090626 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20090626 Address after: Delaware Patentee after: Aventis holding company Address before: new jersey Patentee before: Aventis Pharmaceuticals Inc. |
|
ASS | Succession or assignment of patent right |
Owner name: AVENTIS-SAAB CO.,LTD. Free format text: FORMER OWNER: AVENTIS HOLDINGS CO., LTD. Effective date: 20100526 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: USA DEAWARE STATE TO: DELAWARE, USA |
|
TR01 | Transfer of patent right |
Effective date of registration: 20100526 Address after: Delaware Patentee after: Aventis Pharma Inc. Address before: Delaware, USA Patentee before: Aventis holding company |
|
C17 | Cessation of patent right | ||
CX01 | Expiry of patent term |
Expiration termination date: 20141014 Granted publication date: 19980923 |